BCR:ABL-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS IN CHILDREN AND ADOLESCENTS: INCREASED DISEASE BURDEN IN PATIENTS WITH JAK2 MUTATION, UNMET DIAGNOSTIC NEEDS AND OPTIMAL TREATMENT OPTIONS

Bibliographic Details
Published in:	EJC Paediatric Oncology
Main Authors:	Charikleia Kelaidi, Kondylia Antoniadi, Loizos Petrikkos, Vassilios Papadakis, Maria Ampatzidou, Maria Kourti, Vasiliki Tzotzola, Aikaterini Bountali, Kalliopi Manola, Kalliopi Stefanaki, Sophia Polychronopoulou
Format:	Article
Language:	English
Published:	Elsevier 2023-12-01
Online Access:	http://www.sciencedirect.com/science/article/pii/S2772610X23000399

Similar Items

A CASE OF KRAS-MUTATED JMML WITH HIGH METHYLATION PROFILE AND PERPLEXED CLINICAL COURSE.
by: Vasiliki Tzotzola, et al.
Published: (2023-12-01)

IMMUNOPHENOTYPE IN SAMD9/9L SYNDROME: CORRELATIONS WITH MORPHOLOGY
by: Charikleia Kelaidi, et al.
Published: (2023-12-01)

THERAPY-RELATED MYELODYSPLASTIC SYNDROMES (t-MDS) IN CHILDHOOD: THE EXPERIENCE OF THE HELLENIC STUDY GROUP FOR MDS/JMML/SAA, MEMBER OF THE EWOG-MDS/SAA WORKING GROUP
by: Loizos Petrikkos, et al.
Published: (2023-12-01)

P1556: HYPER -FERRITINEMIA IN PEDIATRIC ONCOLOGY PATIENTS SECONDARY TO TREATMENT: DIAGNOSTIC APPROACH AND OUTCOME
by: I. Grafakos, et al.
Published: (2022-06-01)

P821: LATE ONSET AND/OR LONG LASTING NEUTROPENIA IN CHILDHOOD: CLINICAL AND HEMATOLOGICAL CHARACTERISTICS AND OUTCOMES
by: C. Kelaidi, et al.
Published: (2022-06-01)

Precision Medicine in BCR-ABL1 Negative Myeloproliferative Neoplasms
by: Linet Njue, et al.
Published: (2020-12-01)

Prognostic Factors for Cardiotoxicity among Children with Cancer: Definition, Causes, and Diagnosis with Omics Technologies
by: Kondylia Antoniadi, et al.
Published: (2023-05-01)

BCR::ABL1-negative myeloproliferative neoplasms in the era of next-generation sequencing
by: Aleksandra Mroczkowska-Bękarciak, et al.
Published: (2023-09-01)

P1700: EARLY APPEARANCE OF CARDIOTOXICITY, IN CHILDREN WITH HEMATOLOGICAL MALIGNANCIES (HM)
by: K. Antoniadi, et al.
Published: (2022-06-01)

Expression of the BCR-ABL1 Gene in Patients with Chronic Myeloproliferative Diseases with Signs of Progression
by: LA Kesaeva, et al.
Published: (2018-10-01)

Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases
by: Enrico La Spina, et al.
Published: (2023-02-01)

Genomic profile helps to predict the clonal evolution and outcome of BCR-ABL-negative myeloproliferative neoplasms
by: Xiaodong Guo, et al.
Published: (2025-08-01)

DARS expression in BCR/ABL1-negative myeloproliferative neoplasms and its association with the immune microenvironment
by: Hao Xiong, et al.
Published: (2024-07-01)

AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms
by: Antonia Beitzen-Heineke, et al.
Published: (2021-09-01)

PB2234: EFFECT OF HYDROXYUREA ON INFLAMMATORY MARKERS IN PATIENTS WITH BCR-ABL NEGATIVE MYELOPROLIFERATIVE DISEASES
by: Oguz Altunok, et al.
Published: (2023-08-01)

CCND2 mutations are infrequent events in BCR-ABL1 negative myeloproliferative neoplasm patients
by: Bruno Cassinat, et al.
Published: (2020-05-01)

Clinicopathological spectrum of BCR-ABL-Negative myeloproliferative neoplasms with correlation with janus-associated kinase 2 mutation
by: Roopa Dixith, et al.
Published: (2019-01-01)

VEGF-A, sVEGFR-1, and sVEGFR-2 in BCR-ABL negative myeloproliferative neoplasms
by: Grażyna Gadomska, et al.
Published: (2017-01-01)

Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms
by: Tariq I. Mughal, et al.
Published: (2014-05-01)

Synergic Crosstalk between Inflammation, Oxidative Stress, and Genomic Alterations in BCR–ABL-Negative Myeloproliferative Neoplasm
by: Alessandro Allegra, et al.
Published: (2020-10-01)

Central Nervous System Fungal Diseases in Children with Malignancies: A 16-Year Study from the Infection Working Group of the Hellenic Society of Pediatric Hematology Oncology
by: Loizos Petrikkos, et al.
Published: (2024-09-01)

PB2187: ARTERIAL AND VENOUS THROMBOEMBOLIC COMPLICATIONS IN 832 PATIENTS WITH BCR-ABL-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (MPN)
by: Kai Wille, et al.
Published: (2023-08-01)

Genetic polymorphisms of hemostatic factors and thrombotic risk in non BCR-ABL myeloproliferative neoplasms: A pilot study
by: Dambrauskienė R, et al.
Published: (2017-06-01)

Aberrant Activation-Induced Cytidine Deaminase Gene Expression Links BCR/ABL1-Negative Classical Myeloproliferative Neoplasms
by: Hasan Dermenci, et al.
Published: (2022-06-01)

P1053: NEUTROPHIL-TO-LYMPHOCYTE AND PLATELET-TO-LYMPHOCYTE RATIO AS NOVEL PROGNOSTIC BIOMARKES IN BCR-ABL NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
by: Mirjana Cvetkovic, et al.
Published: (2023-08-01)

Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of <i>BCR::ABL1</i>-Negative Myeloproliferative Neoplasm
by: Norman Abbou, et al.
Published: (2022-12-01)

The frequency of calreticulin and mpl gene mutations in bcr-abl and jak2 unmutated chronic myeloproliferative neoplasms and its effect on the outcome
by: T. Tiryaki, et al.
Published: (2020-10-01)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
by: Shohei Kawakami, et al.
Published: (2022-01-01)

PB2191: A RETROSPECTIVE MULTI-CENTER STUDY ON DIRECT ORAL ANTICOAGULANT USE IN BCR::ABL1 NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
by: Mehmet Baysal, et al.
Published: (2023-08-01)

Chronic myeloproliferative neoplasms with concomitant CALR mutation and BCR::ABL1 translocation: diagnostic and therapeutic implications of a rare hybrid disease
by: Magda Zanelli, et al.
Published: (2024-03-01)

Monitoring BCR-ABL transcript levels by real-time quantitative polymerase chain reaction: a linear regression equation to convert from BCR-ABL/B2M ratio to estimated BCR-ABL/ABL ratio
by: Ilaria Iacobucci, et al.
Published: (2007-03-01)

Combined targeting of GPX4 and BCR-ABL tyrosine kinase selectively compromises BCR-ABL+ leukemia stem cells
by: Chengwu Zeng, et al.
Published: (2024-10-01)

An In-house Method for Molecular Monitoring of BCR-ABL
by: Hakkı Ogun Sercan, et al.
Published: (2012-12-01)

The other Achilles’ heel of BCR-ABL1
by: Kim De Keersmaecker
Published: (2012-01-01)

Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow
by: Susanne Schnittger, et al.
Published: (2012-10-01)

Detection of ABL1 deletion without BCR-ABL rearrangement in ETP-ALL
by: Ahmed Makboul, et al.
Published: (2024-10-01)

Insights from a rare myeloproliferative neoplasm with coexisting BCR‐ABL1 fusion gene, CALR, and TET2 mutations treated with nilotinib and ruxolitinib
by: Li Huo, et al.
Published: (2023-01-01)

CML-like biology: BCR::ABL1 and beyond...
by: Jan Zuna
Published: (2025-10-01)

Mutant BCR-ABL clones in chronic myeloid leukemia
by: Michael S. Mathisen, et al.
Published: (2011-03-01)

Co-occurrence of JAK2-V617 F mutation and BCR::ABL1 translocation in chronic myeloproliferative neoplasms: a potentially confounding genetic combination
by: Magda Zanelli, et al.
Published: (2024-01-01)